Real‐World Off‐Label Use of Letermovir Prophylaxis for Cytomegalovirus Prevention in Non‐Kidney Solid Organ Transplant Recipients: Outcomes, Safety, and Review of Literature

Documenti analoghi

• Risk Factors and Outcomes of Recurrent Cytomegalovirus Infection in Heart Transplant Recipients
  di: Vaisak O. Nair, et al.
  Pubblicazione: (2025)
• Letermovir Conversion for Cytomegalovirus Prophylaxis in Solid Organ Transplant
  di: Suneri J. Amin, et al.
  Pubblicazione: (2025)
• Survey of Post‐Prophylaxis Delayed‐Onset Cytomegalovirus Management Strategies Among Transplant Providers
  di: Lemuel R. Non, et al.
  Pubblicazione: (2024)
• De Novo Letermovir for Cytomegalovirus Prophylaxis in High‐Risk Liver Transplant Recipients
  di: Hanna L. Kleiboeker, et al.
  Pubblicazione: (2025)
• Use of Letermovir as Secondary Prophylaxis in Cytomegalovirus Resistant Pediatric Heart Transplant Recipients
  di: John‐Anthony Coppola, et al.
  Pubblicazione: (2025)